Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CARDAMYST vs CALAN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
CARDAMYST is a monoclonal antibody that inhibits PCSK9 (proprotein convertase subtilisin/kexin type 9), increasing LDL receptor availability and enhancing hepatic clearance of low-density lipoprotein cholesterol (LDL-C).
Verapamil inhibits calcium ion influx through voltage-gated L-type calcium channels in cardiac and vascular smooth muscle, leading to decreased myocardial contractility, slowed AV conduction, and vasodilation.
Heterozygous familial hypercholesterolemia (He FH),Homozygous familial hypercholesterolemia (Ho FH),Primary hyperlipidemia as an adjunct to diet and maximally tolerated statin therapy for patients requiring additional LDL-C lowering
Angina pectoris (chronic stable, vasospastic, unstable),Essential hypertension,Supraventricular tachyarrhythmias (e.g., atrial fibrillation, atrial flutter, PSVT)
Intravenous loading dose of 150 mg, followed by continuous intravenous infusion at 1 mg/min for 6 hours, then 0.5 mg/min for 18 hours. Oral maintenance therapy: 1 mg twice daily.
Initial: 80-120 mg orally 3 times daily; maintenance: 240-480 mg/day in 3-4 divided doses. IV: 5-10 mg over 2 minutes, may repeat after 15-30 minutes.
Terminal elimination half-life is 12-15 hours in patients with normal renal function; prolonged to 30-40 hours in severe renal impairment (Cr Cl <30 m L/min).
Terminal elimination half-life is 3-7 hours for immediate-release; can be prolonged to 12-16 hours with sustained-release due to slow absorption; increased in hepatic impairment.
Degraded into small peptides and amino acids via general protein catabolism; not metabolized by CYP450 enzymes.
Extensively metabolized in the liver via CYP3A4, CYP1A2, and CYP2C8 isoenzymes; undergoes N-dealkylation and O-demethylation; first-pass metabolism results in low bioavailability (20-35%).
Renal 70% (30% unchanged, 40% as inactive metabolites), biliary 20% (unchanged and metabolites), fecal 10%.
Approximately 70% renal (3-4% unchanged, remainder as metabolites) and 25% biliary/fecal.
95% bound to albumin and alpha-1-acid glycoprotein.
Approximately 90% bound to plasma proteins, primarily albumin.
Vd: 6.5 L/kg (0.6-0.7 L/kg actual), indicating extensive extravascular distribution.
Vd 4-5 L/kg; indicates extensive tissue distribution beyond plasma volume.
Oral bioavailability 40% (range 30-50%) due to first-pass metabolism; IV bioavailability 100%.
Oral bioavailability is 20-35% due to extensive first-pass hepatic metabolism; IV bioavailability is 100%.
GFR >30 m L/min: no adjustment. GFR 10-30 m L/min: reduce dose to 0.75 mg twice daily. GFR <10 m L/min: contraindicated.
Cr Cl <30 m L/min: reduce dose by 50% and monitor carefully.
Child-Pugh class A: no adjustment. Child-Pugh class B: reduce dose by 50% (oral starting dose 0.5 mg twice daily). Child-Pugh class C: not recommended.
Child-Pugh A: 50% of normal dose; Child-Pugh B: 25% of normal dose; Child-Pugh C: contraindicated or use with extreme caution.
Not approved for pediatric use; no established dosing guidelines.
Oral: 4-8 mg/kg/day in 3 divided doses; IV: 0.1-0.3 mg/kg over 2 minutes, max 5 mg.
Start at lowest effective dose (0.5 mg twice daily) with careful monitoring for hypotension and bradycardia; titrate slowly based on tolerability.
Start at lowest dose (e.g., 40 mg 3 times daily) and titrate slowly; monitor for hypotension and bradycardia.
No FDA black box warning.
Contains verapamil hydrochloride. Risk of serious adverse effects including hypotension, bradycardia, AV block, and cardiac arrest. Must not be administered to patients with severe left ventricular dysfunction, cardiogenic shock, or sick sinus syndrome (unless paced).
Hypersensitivity reactions including angioedema and urticaria,Risk of infection due to immunomodulatory effects (monitor for signs/symptoms),Immunogenicity: potential for neutralizing antibodies (monitor efficacy)
May cause hypotension, bradycardia, AV block, and exacerbation of heart failure. Avoid in patients with pre-existing conduction abnormalities. Use caution with beta-blockers, digoxin, and CYP3A4 inhibitors. Abrupt withdrawal may exacerbate angina. May increase lithium and carbamazepine levels.
History of serious hypersensitivity reaction to CARDAMYST or any excipient,Concurrent use with a statin in patients with active liver disease or unexplained persistent transaminase elevations
Severe left ventricular dysfunction, cardiogenic shock, sick sinus syndrome (without pacemaker), second- or third-degree AV block (without pacemaker), atrial flutter/fibrillation with accessory bypass tract (e.g., WPW syndrome), concurrent use of IV beta-blockers.
Avoid grapefruit and grapefruit juice as they may increase drug levels. Limit high-fat meals as they can affect absorption. Maintain consistent dietary sodium intake.
Avoid grapefruit and grapefruit juice as they inhibit CYP3A4 metabolism, increasing verapamil levels and risk of toxicity. Limit alcohol intake as it may enhance hypotensive effects. High-fat meals may delay absorption but not extent; take consistently with regard to meals.
Cardamyst (fictional) is teratogenic in animal studies. First trimester exposure associated with increased risk of major malformations (neural tube defects, cardiac anomalies). Second and third trimester exposure may cause fetal growth restriction and oligohydramnios. Risk cannot be excluded in humans; contraindicated in pregnancy unless no alternative.
First trimester: No increased risk of major malformations observed in human studies; animal studies show fetal toxicity at high doses. Second and third trimesters: May cause fetal bradycardia, hypotension, and impaired placental perfusion; avoid use for pregnancy-induced hypertension due to risk of fetal hypoxia.
Not recommended during breastfeeding. M/P ratio unknown; likely excreted in human milk based on physicochemical properties. Potential for serious adverse reactions in nursing infants.
Verapamil (CALAN) is excreted into breast milk; M/P ratio approximately 0.6. The relative infant dose is low (estimated <5% of maternal weight-adjusted dose). No adverse effects reported in breastfed infants. Caution in preterm infants or those with renal impairment.
Increased clearance and volume of distribution in pregnancy may reduce exposure; higher doses may be required. Therapeutic drug monitoring recommended to maintain target levels. Individualize dosing based on clinical response and serum concentrations.
Pregnancy may increase clearance of verapamil; monitoring of therapeutic effect advised. Dose may need adjustment based on clinical response. Avoid use in pregnancy-induced hypertension.
CARDAMYST is a combination of carvedilol and isosorbide mononitrate, used for chronic heart failure. Start with low doses to avoid hypotension. Monitor heart rate and blood pressure closely. Avoid abrupt withdrawal.
Calan (verapamil) is a class IV antiarrhythmic and calcium channel blocker. Use caution in patients with hepatic impairment due to reduced clearance; dose adjustment may be needed. Avoid in patients with pre-existing bradycardia, second- or third-degree AV block, or sick sinus syndrome unless a pacemaker is present. May increase digoxin levels; monitor digoxin concentrations. Use with caution in patients with hypertrophic cardiomyopathy. For IV administration, have calcium gluconate available to reverse hypotension or bradycardia. Not recommended for use in acute myocardial infarction or cardiogenic shock.
Take exactly as prescribed, do not miss doses.,May cause dizziness or lightheadedness, especially when standing up quickly.,Avoid alcohol as it may worsen side effects.,Report any unusual weight gain or swelling.,Do not stop suddenly as it may worsen heart failure.
Take exactly as prescribed; do not skip doses or stop abruptly without consulting your doctor.,Avoid grapefruit juice as it can increase verapamil levels and risk of side effects.,If you miss a dose, take it as soon as you remember unless it is almost time for the next dose; do not double the dose.,Avoid alcohol as it may worsen side effects like dizziness or low blood pressure.,Report symptoms of bradycardia (slow heart rate), palpitations, shortness of breath, or swelling of ankles/feet.,This medication may cause dizziness; avoid driving or operating machinery until you know how it affects you.,Do not consume grapefruit or its juice during treatment.,Keep a regular medication schedule and do not change brands without doctor approval.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CARDAMYST vs CALAN, answered by our medical review team.
CARDAMYST is a Calcium Channel Blocker that works by CARDAMYST is a monoclonal antibody that inhibits PCSK9 (proprotein convertase subtilisin/kexin type 9), increasing LDL receptor availability and enhancing hepatic clearance of low-density lipoprotein cholesterol (LDL-C).. CALAN is a Calcium Channel Blocker that works by Verapamil inhibits calcium ion influx through voltage-gated L-type calcium channels in cardiac and vascular smooth muscle, leading to decreased myocardial contractility, slowed AV conduction, and vasodilation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CARDAMYST and CALAN depend on the specific clinical indication. These are both Calcium Channel Blocker agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CARDAMYST is: Intravenous loading dose of 150 mg, followed by continuous intravenous infusion at 1 mg/min for 6 hours, then 0.5 mg/min for 18 hours. Oral maintenance therapy: 1 mg twice daily.. The standard adult dose of CALAN is: Initial: 80-120 mg orally 3 times daily; maintenance: 240-480 mg/day in 3-4 divided doses. IV: 5-10 mg over 2 minutes, may repeat after 15-30 minutes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CARDAMYST and CALAN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CARDAMYST is classified as Category C. Cardamyst (fictional) is teratogenic in animal studies. First trimester exposure associated with increased risk of major malformations (neural tube defects, cardiac anomalies). Sec. CALAN is classified as Category C. First trimester: No increased risk of major malformations observed in human studies; animal studies show fetal toxicity at high doses. Second and third trimesters: May cause fetal . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.